A1 Refereed original research article in a scientific journal

High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer




AuthorsCarpén T., Sorsa T., Jouhi L., Tervahartiala T., Haglund C., Syrjänen S., Tarkkanen J., Mohamed H., Mäkitie A., Hagström J., Mattila P.S.

PublisherSPRINGER

Publication year2019

JournalCancer Immunology, Immunotherapy

Journal name in sourceCANCER IMMUNOLOGY IMMUNOTHERAPY

Journal acronymCANCER IMMUNOL IMMUN

Volume68

Issue8

First page 1263

Last page1272

Number of pages10

ISSN0340-7004

DOIhttps://doi.org/10.1007/s00262-019-02362-4

Web address https://link.springer.com/article/10.1007/s00262-019-02362-4

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/41654684


Abstract
Background: An emerging subset of oropharyngeal squamous cell carcinomas (OPSCC) is caused by HPV. HPV-positive OPSCC has a better prognosis than HPV-negative OPSCC, but other prognostic markers for these two different diseases are scarce. Our aim was to evaluate serum levels and tumor expression of matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and to assess their prognostic role in HPV-positive and HPV-negative OPSCC.

Materials and methods: A total of 90 consecutive OPSCC patients diagnosed and treated with curative intent at the Helsinki University Hospital between 2012 and 2016 were included. Serum samples were prospectively collected. An immunofluorometric assay and an enzyme-linked immunosorbent assay were used to determine MMP-8 and TIMP-1 serum concentrations, respectively. HPV status of the tumors was determined using a combination of HPV-DNA genotyping and p16-INK4a immunohistochemistry. The endpoints were overall survival (OS) and disease-free survival (DFS).

Results: High TIMP-1 serum levels were strongly and independently associated with poorer OS (adjusted HR 14.7, 95% CI 1.8-117.4, p = 0.011) and DFS (adjusted HR 8.7, 95% CI 1.3-57.1, p = 0.024) among HPV-negative patients; this association was not observed in HPV-positive OPSCC. Although TIMP-1 was immunoexpressed in the majority of the tumor tissue samples, the level of immunoexpression was not associated with prognosis, nor did MMP-8 serum levels.
Conclusion: Our results indicate that serum TIMP-1 levels may serve as an independent prognostic marker for HPV-negative OPSCC patients.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 22:22